(RGEN) Repligen - Overview
Sector: HealthcareIndustry: Medical Instruments & Supplies | Exchange NASDAQ (USA) | Currency USD | Market Cap: 6.554m | Total Return -19.7% in 12m
Stock: Bioprocessing, Chromatography, Filtration, Analytics
Total Rating 44
Risk 87
Buy Signal -1.22
| Risk 5d forecast | |
|---|---|
| Volatility | 48.6% |
| Relative Tail Risk | -8.47% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.31 |
| Alpha | -32.98 |
| Character TTM | |
|---|---|
| Beta | 0.901 |
| Beta Downside | -0.115 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.75% |
| CAGR/Max DD | -0.28 |
EPS (Earnings per Share)
Revenue
Risks
Fundamental:
P/E ratio: 135.2907
Description: RGEN Repligen March 05, 2026
Repligen Corporation (RGEN) is a life sciences company specializing in bioprocessing technologies. The company develops and commercializes products used in the manufacturing of biologics.
Its product portfolio includes Protein A ligands, cell culture growth factors, and chromatography products like OPUS pre-packed columns. These are essential for purifying biological molecules in drug development.
Repligen also provides filtration products, such as XCell ATF Cell Retention Systems and TangenX flat sheet cassettes, which are critical for cell culture processing and drug concentration. The bioprocessing sector is a key enabler for the biotechnology and pharmaceutical industries.
Additionally, the company offers process analytics tools, including slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. Repligen sells to life sciences, biopharmaceutical, and diagnostics companies, as well as contract manufacturing organizations.
The company has a collaboration with Navigo Proteins GmbH to develop affinity ligands. Consider exploring ValueRay for further in-depth analysis.
Headlines to watch out for
- Bioprocessing technology demand drives revenue growth
- Biologics purification product sales impact financial performance
- Cell culture growth factor adoption boosts market share
- Regulatory changes in life sciences sector pose risk
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 48.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -2.05 > 1.0 |
| NWC/Revenue: 135.7% < 20% (prev 149.2%; Δ -13.50% < -1%) |
| CFO/TA 0.04 > 3% & CFO 117.4m > Net Income 48.9m |
| Net Debt (123.9m) to EBITDA (176.6m): 0.70 < 3 |
| Current Ratio: 8.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.5m) vs 12m ago 0.83% < -2% |
| Gross Margin: 50.91% > 18% (prev 0.42%; Δ 5.05k% > 0.5%) |
| Asset Turnover: 25.55% > 50% (prev 22.25%; Δ 3.30% > 0%) |
| Interest Coverage Ratio: 1.88 > 6 (EBITDA TTM 176.6m / Interest Expense TTM 44.8m) |
Altman Z'' 3.49
| A: 0.34 (Total Current Assets 1.14b - Total Current Liabilities 135.8m) / Total Assets 2.95b |
| B: 0.15 (Retained Earnings 456.2m / Total Assets 2.95b) |
| C: 0.03 (EBIT TTM 84.3m / Avg Total Assets 2.89b) |
| D: 0.54 (Book Value of Equity 454.3m / Total Liabilities 843.6m) |
| Altman-Z'' Score: 3.49 = A |
Beneish M -3.08
| DSRI: 1.01 (Receivables 158.6m/134.1m, Revenue 738.3m/629.7m) |
| GMI: 0.82 (GM 50.91% / 41.59%) |
| AQI: 1.01 (AQ_t 0.51 / AQ_t-1 0.51) |
| SGI: 1.17 (Revenue 738.3m / 629.7m) |
| TATA: -0.02 (NI 48.9m - CFO 117.4m) / TA 2.95b) |
| Beneish M-Score: -3.08 (Cap -4..+1) = AA |
What is the price of RGEN shares?
As of March 29, 2026, the stock is trading at USD 110.12 with a total of 797,926 shares traded.
Over the past week, the price has changed by -3.30%, over one month by -14.46%, over three months by -33.55% and over the past year by -19.69%.
Over the past week, the price has changed by -3.30%, over one month by -14.46%, over three months by -33.55% and over the past year by -19.69%.
Is RGEN a buy, sell or hold?
Repligen has received a consensus analysts rating of 4.26.
Therefore, it is recommended to buy RGEN.
- StrongBuy: 10
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RGEN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 185.7 | 68.7% |
| Analysts Target Price | 185.7 | 68.7% |
RGEN Fundamental Data Overview March 25, 2026
P/E Trailing = 135.2907
P/E Forward = 57.4713
P/S = 8.8778
P/B = 3.044
P/EG = 8.2343
Revenue TTM = 738.3m USD
EBIT TTM = 84.3m USD
EBITDA TTM = 176.6m USD
Long Term Debt = 542.2m USD (from longTermDebt, last quarter)
Short Term Debt = 21.6m USD (from shortTermDebt, last quarter)
Debt = 689.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 123.9m USD (from netDebt column, last quarter)
Enterprise Value = 6.48b USD (6.55b + Debt 689.9m - CCE 767.6m)
Interest Coverage Ratio = 1.88 (Ebit TTM 84.3m / Interest Expense TTM 44.8m)
EV/FCF = 70.91x (Enterprise Value 6.48b / FCF TTM 91.3m)
FCF Yield = 1.41% (FCF TTM 91.3m / Enterprise Value 6.48b)
FCF Margin = 12.37% (FCF TTM 91.3m / Revenue TTM 738.3m)
Net Margin = 6.62% (Net Income TTM 48.9m / Revenue TTM 738.3m)
Gross Margin = 50.91% ((Revenue TTM 738.3m - Cost of Revenue TTM 362.4m) / Revenue TTM)
Gross Margin QoQ = 47.21% (prev 53.24%)
Tobins Q-Ratio = 2.20 (Enterprise Value 6.48b / Total Assets 2.95b)
Interest Expense / Debt = 0.86% (Interest Expense 5.91m / Debt 689.9m)
Taxrate = 30.48% (5.83m / 19.1m)
NOPAT = 58.6m (EBIT 84.3m * (1 - 30.48%))
Current Ratio = 8.37 (Total Current Assets 1.14b / Total Current Liabilities 135.8m)
Debt / Equity = 0.33 (Debt 689.9m / totalStockholderEquity, last quarter 2.11b)
Debt / EBITDA = 0.70 (Net Debt 123.9m / EBITDA 176.6m)
Debt / FCF = 1.36 (Net Debt 123.9m / FCF TTM 91.3m)
Total Stockholder Equity = 2.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.69% (Net Income 48.9m / Total Assets 2.95b)
RoE = 2.37% (Net Income TTM 48.9m / Total Stockholder Equity 2.06b)
RoCE = 3.24% (EBIT 84.3m / Capital Employed (Equity 2.06b + L.T.Debt 542.2m))
RoIC = 2.26% (NOPAT 58.6m / Invested Capital 2.59b)
WACC = 8.34% (E(6.55b)/V(7.24b) * Re(9.15%) + D(689.9m)/V(7.24b) * Rd(0.86%) * (1-Tc(0.30)))
Discount Rate = 9.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.63%
[DCF] Terminal Value 80.50% ; FCFF base≈113.0m ; Y1≈139.4m ; Y5≈237.8m
[DCF] Fair Price = 65.65 (EV 3.82b - Net Debt 123.9m = Equity 3.70b / Shares 56.3m; r=8.34% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -62.46 | EPS CAGR: -15.46% | SUE: 0.41 | # QB: 0
Revenue Correlation: -20.24 | Revenue CAGR: -1.11% | SUE: 1.87 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.47 | Chg7d=-0.000 | Chg30d=-0.025 | Revisions Net=-9 | Analysts=17
EPS current Year (2026-12-31): EPS=1.96 | Chg7d=+0.000 | Chg30d=-0.090 | Revisions Net=-12 | Growth EPS=+14.8% | Growth Revenue=+11.9%
EPS next Year (2027-12-31): EPS=2.51 | Chg7d=-0.013 | Chg30d=-0.119 | Revisions Net=-5 | Growth EPS=+27.8% | Growth Revenue=+14.9%
[Analyst] Revisions Ratio: -0.69 (2 Up / 11 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 8.4% (Discount Rate 9.2% - Earnings Yield 0.7%)
[Growth] Growth Spread = +3.1% (Analyst 11.5% - Implied 8.4%)
P/E Forward = 57.4713
P/S = 8.8778
P/B = 3.044
P/EG = 8.2343
Revenue TTM = 738.3m USD
EBIT TTM = 84.3m USD
EBITDA TTM = 176.6m USD
Long Term Debt = 542.2m USD (from longTermDebt, last quarter)
Short Term Debt = 21.6m USD (from shortTermDebt, last quarter)
Debt = 689.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 123.9m USD (from netDebt column, last quarter)
Enterprise Value = 6.48b USD (6.55b + Debt 689.9m - CCE 767.6m)
Interest Coverage Ratio = 1.88 (Ebit TTM 84.3m / Interest Expense TTM 44.8m)
EV/FCF = 70.91x (Enterprise Value 6.48b / FCF TTM 91.3m)
FCF Yield = 1.41% (FCF TTM 91.3m / Enterprise Value 6.48b)
FCF Margin = 12.37% (FCF TTM 91.3m / Revenue TTM 738.3m)
Net Margin = 6.62% (Net Income TTM 48.9m / Revenue TTM 738.3m)
Gross Margin = 50.91% ((Revenue TTM 738.3m - Cost of Revenue TTM 362.4m) / Revenue TTM)
Gross Margin QoQ = 47.21% (prev 53.24%)
Tobins Q-Ratio = 2.20 (Enterprise Value 6.48b / Total Assets 2.95b)
Interest Expense / Debt = 0.86% (Interest Expense 5.91m / Debt 689.9m)
Taxrate = 30.48% (5.83m / 19.1m)
NOPAT = 58.6m (EBIT 84.3m * (1 - 30.48%))
Current Ratio = 8.37 (Total Current Assets 1.14b / Total Current Liabilities 135.8m)
Debt / Equity = 0.33 (Debt 689.9m / totalStockholderEquity, last quarter 2.11b)
Debt / EBITDA = 0.70 (Net Debt 123.9m / EBITDA 176.6m)
Debt / FCF = 1.36 (Net Debt 123.9m / FCF TTM 91.3m)
Total Stockholder Equity = 2.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.69% (Net Income 48.9m / Total Assets 2.95b)
RoE = 2.37% (Net Income TTM 48.9m / Total Stockholder Equity 2.06b)
RoCE = 3.24% (EBIT 84.3m / Capital Employed (Equity 2.06b + L.T.Debt 542.2m))
RoIC = 2.26% (NOPAT 58.6m / Invested Capital 2.59b)
WACC = 8.34% (E(6.55b)/V(7.24b) * Re(9.15%) + D(689.9m)/V(7.24b) * Rd(0.86%) * (1-Tc(0.30)))
Discount Rate = 9.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.63%
[DCF] Terminal Value 80.50% ; FCFF base≈113.0m ; Y1≈139.4m ; Y5≈237.8m
[DCF] Fair Price = 65.65 (EV 3.82b - Net Debt 123.9m = Equity 3.70b / Shares 56.3m; r=8.34% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -62.46 | EPS CAGR: -15.46% | SUE: 0.41 | # QB: 0
Revenue Correlation: -20.24 | Revenue CAGR: -1.11% | SUE: 1.87 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.47 | Chg7d=-0.000 | Chg30d=-0.025 | Revisions Net=-9 | Analysts=17
EPS current Year (2026-12-31): EPS=1.96 | Chg7d=+0.000 | Chg30d=-0.090 | Revisions Net=-12 | Growth EPS=+14.8% | Growth Revenue=+11.9%
EPS next Year (2027-12-31): EPS=2.51 | Chg7d=-0.013 | Chg30d=-0.119 | Revisions Net=-5 | Growth EPS=+27.8% | Growth Revenue=+14.9%
[Analyst] Revisions Ratio: -0.69 (2 Up / 11 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 8.4% (Discount Rate 9.2% - Earnings Yield 0.7%)
[Growth] Growth Spread = +3.1% (Analyst 11.5% - Implied 8.4%)